# Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration

> **NCT00157976** · PHASE3 · UNKNOWN · sponsor: **Miravant Pharmaceuticals** · enrollment: 660 (—)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Photrex (rostaporfin)

## Key facts

- **NCT ID:** NCT00157976
- **Lead sponsor:** Miravant Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 660 (—)
- **Last updated:** 2005-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00157976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00157976, "Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00157976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*